Terns Pharmaceuticals, a US and Shanghai-based biopharmaceutical start-up, has raised US$80 million in series B round of financing led by Vivo Capital and OrbiMed. New investor Decheng Capital and existing investor Lilly Asia Ventures also participated in this round, according to Terns Pharmaceuticals announcement on its official website. Founded in 2016, Terns Pharmaceuticals is focused […]

Vivo Capital, OrbiMed Lead $80M Series B Round In Biopharmaceutical Start-Up Terns Pharmaceuticals appeared first on China Money Network.